Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #7276
Reference
MSAN(2021)11
Name
Repaglinide 1mg and 2mg tablets
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
PHARMACEUTICAL INDUSTRY
DRUG THERAPY
PHARMACEUTICAL SERVICES
SUPPLIES
Description
1. Generic repaglinide 1mg and 2mg tablets are out of stock until early May 2021.
2. Limited quantities of repaglinide 500 microgram tablets remain available but are unable to support any increase in demand.
3. A limited quantity of Prandin (repaglinide) 500 microgram, 1mg and 2mg tablets remain available but are also unable to support any increase in demand.
4. Unlicensed supplies of repaglinide 1mg and 2mg tablets have been sourced.
5. Prescribers will need to review all affected patients and assess ongoing need for repaglinide. If ongoing treatment is required, consideration should be given to prescribing an alternative glucose lowering medication where unlicensed imports of repaglinide are not appropriate.
2. Limited quantities of repaglinide 500 microgram tablets remain available but are unable to support any increase in demand.
3. A limited quantity of Prandin (repaglinide) 500 microgram, 1mg and 2mg tablets remain available but are also unable to support any increase in demand.
4. Unlicensed supplies of repaglinide 1mg and 2mg tablets have been sourced.
5. Prescribers will need to review all affected patients and assess ongoing need for repaglinide. If ongoing treatment is required, consideration should be given to prescribing an alternative glucose lowering medication where unlicensed imports of repaglinide are not appropriate.
Contact Name
Contact Email
Contact Address
Created
2021-03-16 00:00:00
Click to go back to homepage